X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DR. REDDYS LAB - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DR. REDDYS LAB ORCHID PHARMA LTD/
DR. REDDYS LAB
 
P/E (TTM) x -0.2 31.5 - View Chart
P/BV x 0.2 3.4 4.5% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ORCHID PHARMA LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB
Mar-18
ORCHID PHARMA LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1942,788 7.0%   
Low Rs351,902 1.8%   
Sales per share (Unadj.) Rs276.5860.8 32.1%  
Earnings per share (Unadj.) Rs-79.257.1 -138.8%  
Cash flow per share (Unadj.) Rs-43.5122.0 -35.6%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs53.9757.7 7.1%  
Shares outstanding (eoy) m70.45165.91 42.5%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.7 15.2%   
Avg P/E ratio x-1.441.1 -3.5%  
P/CF ratio (eoy) x-2.619.2 -13.7%  
Price / Book Value ratio x2.13.1 68.6%  
Dividend payout %035.0 0.0%   
Avg Mkt Cap Rs m8,067389,034 2.1%   
No. of employees `0002.823.5 11.9%   
Total wages/salary Rs m2,52732,149 7.9%   
Avg. sales/employee Rs Th6,956.16,070.8 114.6%   
Avg. wages/employee Rs Th902.51,366.6 66.0%   
Avg. net profit/employee Rs Th-1,993.0402.5 -495.2%   
INCOME DATA
Net Sales Rs m19,477142,810 13.6%  
Other income Rs m4071,552 26.2%   
Total revenues Rs m19,884144,362 13.8%   
Gross profit Rs m1,10323,512 4.7%  
Depreciation Rs m2,51910,772 23.4%   
Interest Rs m5,227788 663.3%   
Profit before tax Rs m-6,23613,504 -46.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1254,380 -2.9%   
Profit after tax Rs m-5,5809,468 -58.9%  
Gross profit margin %5.716.5 34.4%  
Effective tax rate %2.032.4 6.2%   
Net profit margin %-28.76.6 -432.2%  
BALANCE SHEET DATA
Current assets Rs m11,014104,984 10.5%   
Current liabilities Rs m32,06068,938 46.5%   
Net working cap to sales %-108.125.2 -428.1%  
Current ratio x0.31.5 22.6%  
Inventory Days Days9574 127.6%  
Debtors Days Days34104 32.4%  
Net fixed assets Rs m29,440104,385 28.2%   
Share capital Rs m705830 84.9%   
"Free" reserves Rs m2,043124,886 1.6%   
Net worth Rs m3,800125,716 3.0%   
Long term debt Rs m9,01825,089 35.9%   
Total assets Rs m46,510225,443 20.6%  
Interest coverage x-0.218.1 -1.1%   
Debt to equity ratio x2.40.2 1,189.2%  
Sales to assets ratio x0.40.6 66.1%   
Return on assets %-0.84.5 -16.7%  
Return on equity %-146.97.5 -1,949.9%  
Return on capital %-3.79.7 -38.5%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51372,623 10.3%   
Fx outflow Rs m5,64918,916 29.9%   
Net fx Rs m1,86553,707 3.5%   
CASH FLOW
From Operations Rs m1,68218,030 9.3%  
From Investments Rs m-9,860-14,883 66.3%  
From Financial Activity Rs m6,644-4,440 -149.6%  
Net Cashflow Rs m-1,535-1,236 124.2%  

Share Holding

Indian Promoters % 32.3 25.5 126.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.4 85.2%  
FIIs % 3.3 35.3 9.3%  
ADR/GDR % 4.6 18.5 24.9%  
Free float % 55.3 15.3 361.4%  
Shareholders   84,811 75,885 111.8%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS